First Trust Advisors LP Cuts Position in Integra LifeSciences Holdings Co. (NASDAQ:IART)

First Trust Advisors LP decreased its position in shares of Integra LifeSciences Holdings Co. (NASDAQ:IARTFree Report) by 13.2% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 561,900 shares of the life sciences company’s stock after selling 85,392 shares during the period. First Trust Advisors LP owned approximately 0.72% of Integra LifeSciences worth $24,471,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Signaturefd LLC grew its position in Integra LifeSciences by 248.5% during the fourth quarter. Signaturefd LLC now owns 582 shares of the life sciences company’s stock valued at $25,000 after acquiring an additional 415 shares during the last quarter. Hexagon Capital Partners LLC raised its position in Integra LifeSciences by 123.3% in the 4th quarter. Hexagon Capital Partners LLC now owns 670 shares of the life sciences company’s stock worth $29,000 after purchasing an additional 370 shares during the period. Gladius Capital Management LP bought a new stake in Integra LifeSciences in the third quarter worth $47,000. Covestor Ltd boosted its position in Integra LifeSciences by 82.5% during the third quarter. Covestor Ltd now owns 2,037 shares of the life sciences company’s stock valued at $78,000 after buying an additional 921 shares during the period. Finally, Mitsubishi UFJ Asset Management UK Ltd. bought a new position in shares of Integra LifeSciences during the fourth quarter valued at about $131,000. 84.78% of the stock is currently owned by hedge funds and other institutional investors.

Integra LifeSciences Stock Down 0.5 %

NASDAQ:IART opened at $30.65 on Tuesday. Integra LifeSciences Holdings Co. has a 1-year low of $22.36 and a 1-year high of $46.75. The firm’s 50-day moving average price is $29.69 and its 200-day moving average price is $36.74. The company has a market capitalization of $2.42 billion, a PE ratio of 61.30, a P/E/G ratio of 1.11 and a beta of 1.17. The company has a debt-to-equity ratio of 1.15, a current ratio of 4.68 and a quick ratio of 3.35.

Integra LifeSciences (NASDAQ:IARTGet Free Report) last issued its quarterly earnings results on Monday, May 6th. The life sciences company reported $0.55 earnings per share for the quarter, meeting the consensus estimate of $0.55. The firm had revenue of $368.90 million during the quarter, compared to the consensus estimate of $361.96 million. Integra LifeSciences had a return on equity of 14.27% and a net margin of 2.63%. The company’s revenue was down 3.2% on a year-over-year basis. During the same period last year, the company earned $0.74 earnings per share. On average, equities analysts predict that Integra LifeSciences Holdings Co. will post 3.03 EPS for the current fiscal year.

Insider Buying and Selling

In other Integra LifeSciences news, Chairman Stuart Essig bought 52,641 shares of the business’s stock in a transaction on Thursday, May 23rd. The shares were acquired at an average cost of $28.49 per share, for a total transaction of $1,499,742.09. Following the purchase, the chairman now owns 487,922 shares in the company, valued at approximately $13,900,897.78. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. 3.10% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on IART shares. Morgan Stanley lowered their target price on Integra LifeSciences from $37.00 to $24.00 and set an “underweight” rating for the company in a research note on Tuesday, May 7th. Bank of America dropped their price objective on Integra LifeSciences from $42.00 to $26.00 and set an “underperform” rating for the company in a research note on Tuesday, May 7th. Oppenheimer downgraded shares of Integra LifeSciences from an “outperform” rating to a “market perform” rating in a research note on Tuesday, May 7th. Citigroup increased their price target on shares of Integra LifeSciences from $24.00 to $28.00 and gave the company a “neutral” rating in a research report on Wednesday, May 22nd. Finally, Wells Fargo & Company downgraded Integra LifeSciences from an “overweight” rating to an “equal weight” rating and reduced their price target for the company from $45.00 to $25.00 in a report on Tuesday, May 7th. Two analysts have rated the stock with a sell rating, five have given a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $35.00.

Read Our Latest Stock Analysis on IART

About Integra LifeSciences

(Free Report)

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.

See Also

Want to see what other hedge funds are holding IART? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Integra LifeSciences Holdings Co. (NASDAQ:IARTFree Report).

Institutional Ownership by Quarter for Integra LifeSciences (NASDAQ:IART)

Receive News & Ratings for Integra LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.